clinical use of niraparib in ovarian cancer
Published 6 years ago • 187 plays • Length 2:35Download video MP4
Download video MP3
Similar videos
-
7:42
case 1: use of maintenance therapy in ovarian cancer
-
1:54
management of niraparib dosing in ovarian cancer
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
3:23
case 1: observation versus maintenance therapy in ovarian cancer
-
3:26
niraparib monotherapy in late-line ovarian cancer
-
1:48
niraparib maintenance therapy in ovarian cancer
-
2:18
parp inhibition in recurrent ovarian cancer
-
1:12
data demonstrate efficacy of 3 parp inhibitors in ovarian cancer
-
6:31
prima: frontline niraparib maintenance therapy in ovarian cancer
-
2:25
results of niraparib/bevacizumab combo in platinum-sensitive recurrent ovarian cancer
-
1:50
niraparib shows positive data, requires different dosing in ovarian cancer
-
3:04
phase ii results for niraparib in heavily pretreated patients with ovarian cancer
-
7:19
combination therapy with niraparib and bevacizumab for ovarian cancer
-
0:57
analyzing the survival benefits of niraparib dose modification in ovarian cancer
-
3:10
overview of engot-ov16/nova of niraparib in ovarian cancer and why the results were not surprising
-
1:38
dr. chase on niraparib as frontline maintenance therapy in ovarian cancer
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
3:58
the potential of parp inhibitors in ovarian cancer: paola-1, prima & velia